How Synageva Can Surprise Big And Become The Leader In Explosive Stem Cell Therapeutics
Synageva could surprise and easily buy out this small stem cell therapeutics company very cheaply before it becomes well known. This little company clearly owns the most powerful clinical trial results in history and has a tiny market cap of $35 million.
When the power of stem cell therapy is soon realized due to trial results below, it is understandable that stem cell therapy is about to change medicine forever.
This is why this $2.00 Stem Cell Stock Will Become $100.
Cesca therapeutics (KOOL) recently announced record shattering clinical trial results from their 17 patient CLI trial:
Before treatment, 100% of patients required amputation
12 months after treatment, 82.4% of patients had no amputation
Pain level before treatment on a scale of 0 to 10 was severe at 7.8
Pain level 12 months after treatment was almost non-existent at 0.2
6-minute walking distance before treatment was 14.5 meters
6-minute walking distance 12 months after treatment was 157meters
Before treatment, 11 patients had gangrene with or without ulceration
12 months after treatment 0 patients had gangrene or ulceration
NEW BLOOD VESSELS WERE REGENERATED AFTER TREATMENT.
THERE WERE NO ADVERSE SIDE EFFECTS.
They have similar results for AMI and orthopedic union and have already filed Pre-IDE with FDA for CLI.
Synageve or Investors can buy Cesca at $20.00 in 12 months when more trial results are announced or they can buy Cesca today at under $2.00.